WHO IRISopen access
Fundamental changes in regulation to improve access to biosimilars
perspectives, biosimilar pharmaceuticals, biological products, drug approval, health policy, drug evaluation, legislation, drug, drug costs
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 336778
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.